Starting November 1, the cost of the NuvaRing will be significantly reduced as it becomes part of the Pharmaceutical Benefits Scheme (PBS). General patients will pay $31.60, while concessional patients will only need to pay $7.70.
The inclusion of the NuvaRing in the PBS aims to address cost concerns, which advocates highlight as a significant factor influencing contraceptive choices.
The changes, particularly those related to long-acting reversible contraceptives, are poised to impact approximately 300,000 women annually, potentially saving them up to $400 in out-of-pocket expenses.
The changes linked to long-acting reversible contraceptives are expected to benefit around 300,000 women each year and save them up to $400 in out-of-pocket costs.
